MiNK Therapeutics to Present Updated Data from Phase 2 Study Testing AgenT-797 in Gastric Cancer at AACR IO Annual Meeting

Rhea-AI Summary

MiNK Therapeutics (NASDAQ: INKT) has been selected to present interim data from its ongoing Phase 2 study at the AACR IO Annual Meeting in Los Angeles. The presentation will focus on their investigation of AgenT-797 in combination with botensilimab and balstilimab (BOT/BAL) for treating refractory gastric cancer patients.

The study specifically targets patients with PD-1 refractory gastroesophageal cancer (GEC) who have received second-line or later treatment. The presentation, scheduled for February 25th, will include biomarker analysis from the trial combining iNKT cell therapy with CTLA-4 and PD-1 inhibitors.

Positive

• Selected for oral presentation at major oncology conference (AACR IO)
• Advancing Phase 2 clinical trial in gastric cancer
• Development of combination therapy targeting multiple pathways

Negative

• None.

NEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that it has been selected for an oral presentation at the upcoming American Association for Cancer Research (AACR) IO Annual Meeting that will take place on February 23-26 in Los Angeles, California. The oral presentation will highlight interim data from the company’s ongoing Phase 2 study testing AgenT-797 in combination with Agenus’ lead therapeutic combination, botensilimab and balstilimab (BOT/BAL), in patients with refractory (2L+) gastric cancer (NCT06251973).

Presentation Details:

Abstract Title: Biomarker analysis from Phase 2 study of AgenT-797 (invariant natural killer T-cells), botensilimab (a Fc-enhanced CTLA-4 Inhibitor) with balstilimab (anti-PD-1) in PD-1 refractory gastroesophageal cancer (GEC)

Session: Proffered Papers, Session 2

Date and Time: Tuesday, February 25^th, 1:00-1:45 p.m. PST

About MiNK Therapeutics

MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, visit https://minktherapeutics.com/ or @MiNK_iNKT. Information that may be important to investors will be routinely posted on our website and social media channels.

About AgenT-797

AgenT-797 is an allogeneic invariant natural killer T (iNKT) cell therapy, leveraging a unique innate immune cell type that serves as a master regulator of both innate and adaptive immunity. iNKTs combine the cytotoxic capabilities of natural killer (NK) cells with the adaptive memory of T cells, enabling them to elicit a broad range of immune responses in a pathogen-agnostic manner.

AgenT-797 is a scalable, “off-the-shelf” cell therapy product, manufactured by MiNK Therapeutics in Lexington, MA, to deliver transformative treatment solutions to patients.

Forward Looking Statements

This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the therapeutic potential, anticipated benefit, plans and timelines of iNKT cells and encrypted RNA, as well as the collaboration between MiNK and Autonomous Therapeutics. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These forward-looking statements are subject to risks and uncertainties, including the factors described under the Risk Factors section of the most recent Form 10-K, Form 10-Q and the S-1 Registration Statement filed with the SEC. MiNK cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and MiNK and Autonomous undertake no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

Investor Contact
917-362-1370
investor@minktherapeutics.com

Media Contact
781-674-4428
communications@minktherapeutics.com

FAQ

What is the Phase 2 study of INKT's AgenT-797 investigating?

The Phase 2 study is investigating AgenT-797 in combination with botensilimab and balstilimab for treating second-line or later (2L+) refractory gastric cancer patients.

When will MiNK Therapeutics present their Phase 2 gastric cancer data?

MiNK Therapeutics will present their Phase 2 data on February 25th, 2025, from 1:00-1:45 p.m. PST at the AACR IO Annual Meeting in Los Angeles.

What type of cancer patients are included in INKT's Phase 2 trial?

The trial includes patients with PD-1 refractory gastroesophageal cancer (GEC) who have received second-line or later treatment.

What combination therapy is being tested in INKT's Phase 2 gastric cancer trial?

The trial is testing AgenT-797 (iNKT cells) in combination with botensilimab (CTLA-4 inhibitor) and balstilimab (anti-PD-1).